Clinical experiences with Penberol (cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid) administered to patients with advanced neoplasias.
D000179:Acrylates / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003085:Colic / Q000139:chemically induced; D003967:Diarrhea / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007958:Leukocyte Count; D008175:Lung Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D012004:Rectal Neoplasms / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D013945:Thymoma / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D000179:Acrylates; D000970:Antineoplastic Agents; C012473:Penberol